Spyre Therapeutics, Inc.
AGLE
Revenue
0.00
0.000.00%
3 Months ChangeAssets
608.48M
▲187.40M▲44.50%
3 Months ChangeLiabilities
90.68M
▼-3.02M▼-3.22%
3 Months ChangeFree Cash Flow
-26.30M
▼-6.32M▼-31.63%
12 Months ChangeRevenue/Cost Of Revenue
Loading...
Net Profit/Loss
Loading...
Assets/Liabilities
Loading...
Cash Flows
Loading...
Loading...
Loading...
Recent Quarterly and Annual Filings
2024-05-30
Form 8-K
ID: 0001193125-24-150395
2024-05-15
Form 8-K
ID: 0001193125-24-138893
2024-05-09
Form 8-K
ID: 0001636282-24-000039
2024-05-09
Form 10-Q
ID: 0001636282-24-000037
2024-04-25
Form 8-K
ID: 0001193125-24-113954
2024-03-18
Form 8-K
ID: 0001193125-24-069693
2024-02-29
Form 8-K
ID: 0001636282-24-000007
2024-02-05
Form 8-K
ID: 0001193125-24-023462
2024-01-18
Form 8-K
ID: 0001193125-24-010226
2023-12-08
Form 8-K
ID: 0001193125-23-291257